Immunotherapy targeting plasma ASM is protective in a mouse model of Alzheimer’s disease

[1]  Kang Ho Park,et al.  Discovery of a dual-action small molecule that improves neuropathological features of Alzheimer’s disease mice , 2022, Proceedings of the National Academy of Sciences.

[2]  T. Minamino,et al.  Role of circulating molecules in age-related cardiovascular and metabolic disorders , 2022, Inflammation and regeneration.

[3]  C. Soto,et al.  Infusion of blood from mice displaying cerebral amyloidosis accelerates amyloid pathology in animal models of Alzheimer’s disease , 2020, Acta neuropathologica communications.

[4]  H. Jin,et al.  Potential therapeutic target for aging and age-related neurodegenerative diseases: the role of acid sphingomyelinase , 2020, Experimental & Molecular Medicine.

[5]  C. Svendsen,et al.  Rejuvenating the blood and bone marrow to slow aging-associated cognitive decline and Alzheimer’s disease , 2020, Communications Biology.

[6]  C. Iadecola,et al.  Th17 and Cognitive Impairment: Possible Mechanisms of Action , 2019, Front. Neuroanat..

[7]  Fengyan Xu,et al.  Young Blood Rescues the Cognition of Alzheimer's Model Mice by Restoring the Hippocampal Cholinergic Circuit , 2019, Neuroscience.

[8]  A. Calignano,et al.  Neutralization of IL‐17 rescues amyloid‐β‐induced neuroinflammation and memory impairment , 2019, British journal of pharmacology.

[9]  Liang-Jun Yan,et al.  Circulating factors in young blood as potential therapeutic agents for age-related neurodegenerative and neurovascular diseases , 2019, Brain Research Bulletin.

[10]  S. Quake,et al.  Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1 , 2019, Nature Medicine.

[11]  L. Tian,et al.  Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical Trial , 2019, JAMA neurology.

[12]  D. Janigro,et al.  IFN-γ, IL-17A, or zonulin rapidly increase the permeability of the blood-brain and small intestinal epithelial barriers: Relevance for neuro-inflammatory diseases. , 2018, Biochemical and biophysical research communications.

[13]  Kang Ho Park,et al.  Vascular and Neurogenic Rejuvenation in Aging Mice by Modulation of ASM , 2018, Neuron.

[14]  R. Rad,et al.  Myeloid-derived suppressor cells control B cell accumulation in the CNS during autoimmunity , 2018, Nature Immunology.

[15]  X. Yao,et al.  Blood-derived amyloid-β protein induces Alzheimer’s disease pathologies , 2018, Molecular Psychiatry.

[16]  J. Kornhuber,et al.  Imbalance of Circulating Th17 and Regulatory T Cells in Alzheimer’s Disease: A Case Control Study , 2018, Front. Immunol..

[17]  H. Solleiro-Villavicencio,et al.  Effect of Chronic Oxidative Stress on Neuroinflammatory Response Mediated by CD4+T Cells in Neurodegenerative Diseases , 2018, Front. Cell. Neurosci..

[18]  E. Sigurdsson,et al.  Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice , 2017, Scientific Reports.

[19]  Arash Pourgholaminejad,et al.  The role of Th17 cells in auto-inflammatory neurological disorders , 2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[20]  A. Bai,et al.  Acid sphingomyelinase mediates human CD4+ T-cell signaling: potential roles in T-cell responses and diseases , 2017, Cell Death and Disease.

[21]  Tony Wyss-Coray,et al.  Ageing, neurodegeneration and brain rejuvenation , 2016, Nature.

[22]  E. Masliah,et al.  Preclinical Assessment of Young Blood Plasma for Alzheimer Disease. , 2016, JAMA neurology.

[23]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[24]  H. Akiyama,et al.  Neuropeptide Y Induces Hematopoietic Stem/Progenitor Cell Mobilization by Regulating Matrix Metalloproteinase‐9 Activity Through Y1 Receptor in Osteoblasts , 2016, Stem cells.

[25]  C. Ramírez,et al.  ANGPTL4 deficiency in haematopoietic cells promotes monocyte expansion and atherosclerosis progression , 2016, Nature Communications.

[26]  A. Fischer,et al.  Ly6C(hi) Monocytes Provide a Link between Antibiotic-Induced Changes in Gut Microbiota and Adult Hippocampal Neurogenesis. , 2016, Cell reports.

[27]  K. Plate,et al.  Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma , 2015, EMBO molecular medicine.

[28]  D. Herr,et al.  Role of sphingomyelinases in neurological disorders , 2015, Expert opinion on therapeutic targets.

[29]  D. Catalucci,et al.  Neutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin , 2015, Nature Medicine.

[30]  Gregor Bieri,et al.  β2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis , 2015, Nature Medicine.

[31]  Á. Pascual-Leone,et al.  cis p-tau: early driver of brain injury and tauopathy blocked by antibody , 2015, Nature.

[32]  J. Kornhuber,et al.  Secretory sphingomyelinase in health and disease , 2015, Biological chemistry.

[33]  Magda Tsolaki,et al.  Plasma proteins predict conversion to dementia from prodromal disease , 2014, Alzheimer's & Dementia.

[34]  H. Nakauchi,et al.  Acid sphingomyelinase modulates the autophagic process by controlling lysosomal biogenesis in Alzheimer’s disease , 2014, The Journal of experimental medicine.

[35]  Sung Hoon Baik,et al.  Migration of neutrophils targeting amyloid plaques in Alzheimer's disease mouse model , 2014, Neurobiology of Aging.

[36]  Richard T. Lee,et al.  Vascular and Neurogenic Rejuvenation of the Aging Mouse Brain by Young Systemic Factors , 2014, Science.

[37]  Danielle A. Simmons,et al.  Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice , 2014, Nature Medicine.

[38]  Jean-Philippe Michaud,et al.  Real-time in vivo imaging reveals the ability of monocytes to clear vascular amyloid beta. , 2013, Cell reports.

[39]  M. Schwartz,et al.  How Do Immune Cells Support and Shape the Brain in Health, Disease, and Aging? , 2013, The Journal of Neuroscience.

[40]  Yu-ping Peng,et al.  Th17 Cell-Mediated Neuroinflammation Is Involved in Neurodegeneration of Aβ1-42-Induced Alzheimer’s Disease Model Rats , 2013, PloS one.

[41]  K. Scearce-Levie,et al.  A Therapeutic Antibody Targeting Bace1 Inhibits Amyloid-beta Production in Vivo , 2013 .

[42]  J. Kornhuber,et al.  Acid sphingomyelinase–ceramide system mediates effects of antidepressant drugs , 2013, Nature Medicine.

[43]  R. Watts,et al.  Developing Therapeutic Antibodies for Neurodegenerative Disease , 2013, Neurotherapeutics.

[44]  J. Kolls,et al.  Targeting IL-17 and TH17 cells in chronic inflammation , 2012, Nature Reviews Drug Discovery.

[45]  Murray Grossman,et al.  Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease , 2012, Neurology.

[46]  S. Kaveri,et al.  Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. , 2012, The American journal of pathology.

[47]  B. Xia,et al.  CD4+T Cells: Differentiation and Functions , 2012, Clinical & developmental immunology.

[48]  S. Kaveri,et al.  Biology, Pathogenesis of Autoimmune and Inflammatory Diseases, and Therapeutic Strategies , 2012 .

[49]  J. Kaye,et al.  The aging systemic milieu negatively regulates neurogenesis and cognitive function , 2011, Nature.

[50]  D. Green,et al.  Tuberous sclerosis complex 1 (Tsc1) enforces quiescence of naive T cells to promote immune homeostasis and function , 2011, Nature immunology.

[51]  B. Becher,et al.  RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation , 2011, Nature Immunology.

[52]  K. Scearce-Levie,et al.  A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo , 2011, Science Translational Medicine.

[53]  Todd Davidson,et al.  Generation of Pathogenic Th17 Cells in the Absence of TGF-β Signaling , 2010, Nature.

[54]  Y. Hannun,et al.  Roles and regulation of secretory and lysosomal acid sphingomyelinase. , 2009, Cellular signalling.

[55]  B. Engelhardt,et al.  C-C chemokine receptor 6–regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE , 2009, Nature Immunology.

[56]  D. Littman,et al.  Transcriptional regulatory networks in Th17 cell differentiation. , 2009, Current opinion in immunology.

[57]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[58]  W. Paul,et al.  CD4 T cells: fates, functions, and faults. , 2008, Blood.

[59]  Nathalie Arbour,et al.  Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation , 2007, Nature Medicine.

[60]  J. Richardson,et al.  Cognitive correlates of Aβ deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes , 2004, Brain Research.

[61]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[62]  D. Kabelitz,et al.  Ceramide: does it matter for T cells? , 2002, Trends in immunology.

[63]  G. Schmitz,et al.  Quantitative measurement of different ceramide species from crude cellular extracts by electrospray ionization tandem mass spectrometry (ESI-MS/MS). , 1999, Journal of lipid research.

[64]  E. Schuchman,et al.  Characterization of human acid sphingomyelinase purified from the media of overexpressing Chinese hamster ovary cells. , 1999, Biochimica et biophysica acta.

[65]  D. Perl,et al.  Acid sphingomyelinase deficient mice: a model of types A and B Niemann–Pick disease , 1995, Nature Genetics.

[66]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.